Prof. Kevin Outterson is the founding Executive Director of CARB-X, the world’s leading public-private partnership that accelerates the early-stage development of innovative products to prevent, diagnose and treat bacterial infections. CARB-X has supported more than 100 R&D projects around the world, and 24 of these projects have already reached or surpassed first-in-human clinical trials, including three products already on the market. In 2020, CARB-X was awarded the Innovating for Impact Partnership Award by the Global Health Technologies Coalition. CARB-X funders include the governments of the United States, Germany, United Kingdom, Italy, Canada and Japan, plus Wellcome, the Novo Nordisk Foundation and the Gates Foundation.

Prof. Outterson is also the Austin B. Fletcher Professor of Law at Boston University, where he co-directed the Health Law Program. Prof. Outterson has published more than 100 articles and book chapters on health care law, with a focus on incentive problems related to pharmaceutical products, including push and pull incentives for antimicrobials. He served as a senior author on many key research reports and expert panels on antibiotic innovation. In 2015, Prof. Outterson was given the Leadership Award by the Alliance for the Prudent Use of Antibiotics for his research and advocacy work to stop superbugs.